The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib.
T. Moran
No relevant relationships to disclose
J. J. Sanchez
No relevant relationships to disclose
M. A. Molina
No relevant relationships to disclose
J. Bertran-Alamillo
No relevant relationships to disclose
A. Gimenez Capitan
No relevant relationships to disclose
S. Benlloch
No relevant relationships to disclose
M. Taron
No relevant relationships to disclose
B. Massuti
No relevant relationships to disclose
C. Camps
No relevant relationships to disclose
R. Porta
No relevant relationships to disclose
D. Isla
No relevant relationships to disclose
G. Lopez-Vivanco
No relevant relationships to disclose
I. Bover
No relevant relationships to disclose
M. R. Garcia-Campelo
No relevant relationships to disclose
C. D. Rolfo
No relevant relationships to disclose
F. Salazar
No relevant relationships to disclose
E. Carcereny
No relevant relationships to disclose
F. Cardenal
No relevant relationships to disclose
I. Magri
No relevant relationships to disclose
R. Rosell
No relevant relationships to disclose